Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models

MLA

Keigo Yorozu, et al. “Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models.” Clinical Cancer Research, vol. 17, July 2011, pp. 5060–70. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-10-2927.

APA

Keigo Yorozu, Yoriko Yamashita-Kashima, Koh Furugaki, Mitsue Kurasawa, Masateru Ohta, Shigeyuki Iijima, & Kaori Fujimoto-Ouchi. (2011). Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. Clinical Cancer Research, 17, 5060–5070. https://doi.org/10.1158/1078-0432.ccr-10-2927

Chicago

Keigo Yorozu, Yoriko Yamashita-Kashima, Koh Furugaki, Mitsue Kurasawa, Masateru Ohta, Shigeyuki Iijima, and Kaori Fujimoto-Ouchi. 2011. “Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models.” Clinical Cancer Research 17 (July): 5060–70. doi:10.1158/1078-0432.ccr-10-2927.